The role of intravenous iron in anemia management and transfusion avoidance. (åbner nyt vindue)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Kilde‎: Transfusion 2008;48(5):988-1000.

Indekseret‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (åbner nyt vindue)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (åbner nyt vindue)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Kilde‎: BJU Int 2011;108(10):1582-7.

Indekseret‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (åbner nyt vindue)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (åbner nyt vindue)

Lepor H, Lipkin M, Slova D.

Kilde‎: Urology 2010;75(6):1424-8.

Indekseret‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (åbner nyt vindue)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (åbner nyt vindue)

Nieder AM, Rosenblum N, Lepor H.

Kilde‎: Urology 2001;57(4):737-41.

Indekseret‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (åbner nyt vindue)